MBX Biosciences, Inc. (MBX)
53.49
+0.39
(+0.73%)
USD |
NASDAQ |
Nov 18, 16:00
54.20
+0.71
(+1.33%)
After-Hours: 20:00
MBX Biosciences Total Liabilities (Quarterly) : 27.67M for Sept. 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 27.67M |
| June 30, 2026 | 26.37M |
| March 31, 2026 | 14.94M |
| December 31, 2025 | 15.92M |
| September 30, 2025 | 12.54M |
| June 30, 2025 | 12.28M |
| Date | Value |
|---|---|
| March 31, 2025 | 10.50M |
| December 31, 2024 | 11.09M |
| September 30, 2024 | 11.03M |
| June 30, 2024 | 8.41M |
| March 31, 2024 | 6.01M |
| December 31, 2023 | 4.291M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Ligand Pharmaceuticals, Inc. | 1.276B |
| Xeris Biopharma Holdings, Inc. | 374.44M |
| ANI Pharmaceuticals, Inc. | 930.55M |
| Corcept Therapeutics, Inc. | 200.29M |
| Veru, Inc. | 8.651M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 500.62M |
| Shareholders Equity (Quarterly) | 472.95M |
| Debt to Equity Ratio | 0.007 |
| Current Ratio | 19.58 |
| Net Debt Paydown Yield | -0.02% |